Highlights

 

Appointment of new CEO: Mr. Morten Sundstø is constituted as new CEO with effect from August 18th 2009.

 

EU approval: Approval from EU's" Standing Committee on the Food Chain and Animal Health" for health supplements and enriched food in July 2009. The law text is expected to give the company protection against competition since the approval is related to the production technology.

 

Sales development: Increase in revenue with NOK 11.9 million in first half of 2009 compared to NOK 9.4 million in first half of 2008. The significant increased market interest based on regulatory approvals in Europe, positive research results and high market activity provides the company with a solid basis for the ongoing negotiations with several major regional and global companies. These agreements will create a strong basis for significant sales growth ahead. The order reserve as per June 30th totals NOK 1.6 million, goods that have been invoiced but not delivered. As per today, the 3rd Quarter show a revenue of NOK 5.5 million.

 

Development of the food market: NattoPharma signed in February a strategic co-operation agreement with med Danisco regarding exclusive global sales rights for the food market. Danisco will launch MenaQ7 in September. The co-operation between the companies is very good and there are reasons for having great expectations with respect to MenaQ7 as an ingredient in several types of food in the years ahead.

 

Refinancing: The Company has refinanced the bond loan for an additional 2 year period. Furthermore, a capital increase has been carried out through an issue of 2 million new shares at a subscription price of NOK 3.5 per share. In total, this refinancing has contributed with approximately NOK 10 million in new capital.

 

Appointment of strategic advisor: NattoPharma has appointed HDR Partners in Stockholm as strategic advisor in the process of finding an industrial actor who wishes to enter into a dialog with the aim to purchase the company or to merge with the company, in order to secure the shareholder's value in a best possible way, both with respect to value and choice of transaction for the company and its shareholders.

 

For further information, please contact:

Mr. Morten Sundstø,

CEO

Phone no. +47 950 61 860